Skip to content

Consano Bio

2 viewers · 30d

Total raised

$51.7M

+$34.8M this year

2 filings since 2024 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $34.8M
ROUNDS
2
INVESTORS
18
FOUNDED
2022
HQ
Burlington, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Consano Bio is an early-stage biotechnology startup founded in 2022 and headquartered in Des Moines, Iowa. The company focuses on developing first-in-category biologic therapeutics to treat painful and debilitating orthopedic conditions. Its core strategy is to target the underlying drivers of disease rather than merely addressing symptoms.

What sets it apart

The company's approach is designed to create a healing microenvironment at the injury site by shifting it to an anti-inflammatory state, establishing a new protein matrix, and promoting local cell proliferation to facilitate natural repair.

Funding history

2 rounds
EquityMar 6, 2026
Form D
+$34.8M$51.7M total
SAFE+1Oct 15, 2024
Form D
+$16.8M$16.8M total

Products

1 tracked

C-1101

Biologic Therapeutic

C-1101 is an allogenic, multi-protein therapeutic currently in development. It is engineered to treat orthopedic injuries by modulating the local environment to favor healing and tissue regeneration.

  • Utilizes potent cytokines to shift the microenvironment from a pro-inflammatory to an anti-inflammatory state.
  • Establishes a protein matrix to provide a scaffold for local cell proliferation.
  • Leverages platelet growth factors to stimulate healing processes directly at the site of injury.

Links

WebsiteLinkedInSEC EDGAR filings